respiratory

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

Patients

Protecting continuity of care through sustainable respirator...

More attention is being paid to how care can be delivered in ways that maintain continuity for patients while also being environmentally responsible.

News

EU approval for new asthma drug Exdensur lifts GSK

EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.

R&D

steaming nebulizer mask in hand instructing African American daughter

Advancing RSV and hMPV research through human challenge tria...

Human challenge trials offer a complementary approach, and hVIVO has been at the forefront of this field for decades.

Pulmonary fibrosis drug developer Avalyn files IPO

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Where others missed, AZ's IL-33 drug hits the mark in COPD

Protecting continuity of care through sustainable respirator...

EU approval for new asthma drug Exdensur lifts GSK

Advancing RSV and hMPV research through human challenge tria...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

respiratory

Editor's Picks